18611-72-8

Upstream product

• 109-72-8 n-butyllithium 
• 64248-56-2 1-bromo-2,6-difluorobenzene 
• 372-18-9 1,3-Difluorobenzene 

Downstream Products

• 490038-59-0 (6-chloro-pyridin-3-yl)-(2,6-difluoro-phenyl)-methanone 
• 13670-99-0 2,6-difluoroacetophenone 
• 610296-39-4 1-(2,6-difluoro-phenyl)-1,2,3,4-tetrahydro-isoquinoline 
• 610296-31-6 2-[1-(2,6-Difluoro-phenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-N-(2-fluoro-benzyl)-N-indan-2-yl-acetamide 
• 125173-36-6 bis(2,6-difluorophenyl)-tris(4-methylphenyl)bismuth 
• 356074-75-4 1-(2,6-difluoro-phenyl)-2,3,4,5-tetrakis-(3,5-dimethyl-phenyl)-cyclopenta-2,4-dienol 

Relevant academic research and scientific papers

Lithium diisopropylamide-mediated ortholithiations: Lithium chloride catalysis

Ortholithiations of a range of arenes mediated by lithium diisopropylamide (LDA) in THF at -78 °C reveal substantial accelerations by as little as 0.5 mol % of LiCl (relative to LDA). Substrate dependencies suggest a specific range of reactivity within wh

MODULATORS OF THE GLUCOCORTICOID RECEPTOR

The present invention provides compounds of the formula wherein A is of the formula and X, Y, n, R1-R25 are as described in the specification which are modulators of the glucocorticoid receptor and are thus useful for the treatment o

METHOD FOR METAL-ORGANIC PRODUCTION OF ORGANIC INTERMEDIATE PRODUCTS BY MEANS OF ARYL LITHIUM-BASES

The invention relates to a method for the production of substituted aromatic compounds by producing lithium arylene and by reacting it with suitable electrophiles. The method comprises the following steps (step 1); an aryl lithium compound ( auxiliary base'') is initially produced by reacting a halogen aromatic compound with lithium metal; said compound is subsequently (step 2) reacted for deprotonation of the aromatic substrate in order to form the corresponding lithium aromatic compound which is subsequently (step 3) reacted with a corresponding electrophile to form the desired substituted aromatic compound, see page 2 of the description.

Substituted tetrahydroisoquinolines as C5a receptor modulators

Substituted tetrahydroisoquinolines and related compounds are provided. Such compounds are ligands that may be used to modulate C5a receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathologi